Addiction Biology, Volume 30, Issue 9, September 2025.ABSTRACT Chronic nicotine administration leads to neuroadaptations, an important process in nicotine and tobacco dependence for which treatments are limited. The cysteine pro‐drug, N‐acetyl‐cysteine (NAC), is a promising glutamatergic agent that has shown some clinical efficacy in reducing nicotine use in humans.
Kelsey Stoddart +5 more
wiley +1 more source
Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial—Correction [PDF]
, 2006 openalex +1 more source
Monthly buprenorphine depot injection (SUBLOCADE®) for opioid use disorder during pregnancy
The American Journal on Addictions, Volume 34, Issue 5, Page 485-494, September 2025.Abstract Background and Objectives Untreated opioid use disorder (OUD) in pregnancy is associated with adverse obstetrical outcomes, maternal morbidity, and maternal mortality. This article will inform clinicians about the use of monthly extended‐release buprenorphine (BUP‐XR, SUBLOCADE®) to treat OUD during pregnancy and postpartum.
Melinda Ramage +3 more
wiley +1 more source
Compression‐Expansion: Miniaturization, Modularity, and Logistics Beyond Earth
American Anthropologist, Volume 127, Issue 3, Page 424-434, September 2025.ABSTRACT If the Cold War space race culminated in a return to Earth, at present we are experiencing a renewed interest in space. Drawing on fieldwork among people working in the space sector in Sweden, this article focuses on some of the imaginaries underpinning this resurgence and the contemporary commercialization of space. Specifically, I hone in on
Chakad Ojani
wiley +1 more source
British Journal of Pharmacology, Volume 182, Issue 18, Page 4363-4379, September 2025.Abstract Background and Purpose Emerging literature indicates that simultaneously targeting glucagon‐like peptide‐1 receptors (GLP‐1Rs) and neuropeptide Y receptors (Y1/Y2) may represent a new pharmacotherapeutic approach to treating opioid use disorder (OUD).
Antonia Caffrey +5 more
wiley +1 more source
Effectiveness of nicotinic agonists as desensitizers at presynaptic α4β2- and α4α5β2-nicotinic acetylcholine receptors. [PDF]
Nicotine Tob Res, 2014 Wageman CR, Marks MJ, Grady SR.
europepmc +1 more source
Effect of ABT-594 a Selective Nicotinic Agonist, on Voiding Function in Spinal Cord Injury Rat [PDF]
, 2006 Hyun Rho, Sun-Ju Lee, Sung‐Goo Chang
openalex +1 more source
CNS Neuroscience &Therapeutics, Volume 31, Issue 9, September 2025.The effects of tobacco alkaloids: anatabine, anabasine, and nicotine, were investigated in a model of mitochondrial stress, mimicking cellular pathology accompanying Parkinson's disease development. The alkaloids modulated mitochondrial function and alleviated the hallmarks of mitochondrial stress. However, they acted via slightly different mechanisms.
Dominika Malińska +11 more
wiley +1 more source
Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: Focus on cognition [PDF]
, 2007 Timothy E. Wilens, Michael Decker
openalex +1 more source
Gender and Overdose Risk Factors Among Clients Entering Residential Treatment for Opioid Use
Drug and Alcohol Review, Volume 44, Issue 6, Page 1786-1804, September 2025.ABSTRACT Introduction The period post‐residential treatment for opioid use is associated with heightened risk of overdose. The current study aims to: (i) describe characteristics of men and women attending residential treatment for primary opioid use; (ii) identify classes of clients based on primary opioid and other substance/s of concern and (iii ...
Chloe J. Haynes +9 more
wiley +1 more source